"
Team:WITS-CSIR SA/Project/Achievements
From 2011.igem.org
| Line 115: | Line 115: | ||
<div data-dojo-type="dijit.TitlePane" data-dojo-props="title:'Achievements'"> | <div data-dojo-type="dijit.TitlePane" data-dojo-props="title:'Achievements'"> | ||
| + | Significant achievements:</br> | ||
| + | |||
| + | <p>1) We have submitted 16 biobrick parts to the Registry of Standard Biological Parts. Three new biobrick parts representing our “favourite” biobricks, BBa_K537001, BBa_K537002 and BBa_K537003, have been fully characterized.</p></br> | ||
| + | |||
| + | <p>2) We are the first team to characterize the function of two different types of theophylline-responsive riboswitches, and this was achieved for two separate coding sequences. These riboswitch designs are improvements over previously-developed iGEM riboswitches.</p></br> | ||
| + | |||
| + | <p>3) Theophylline-response riboswitch 2 (thRS2-CheZ, BBa_K537002) was capable of significantly higher activation than Theophylline-response riboswitch 1 (thRS1, BBa_K537001) when expressing motility factor CheZ (37-fold vs 4-fold). Moreover, thRS2 showed 6-fold improved motility function over thRS1 and 1-fold increased chemotactic sensitivity to theophylline.</p></br> | ||
| + | |||
| + | <p>4) Theophylline-responsive riboswitch 2-CheZ (BBa_K537002) represents an ideal biobrick for N-terminal fusion to proteins of interest for theophylline-activated messenger activity. This part could have numerous advantages in several other synthetic biology applications. </p></br> | ||
| + | |||
| + | |||
| + | |||
| + | |||
</div> | </div> | ||
</div> | </div> | ||
Revision as of 12:26, 21 September 2011
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
1) We have submitted 16 biobrick parts to the Registry of Standard Biological Parts. Three new biobrick parts representing our “favourite” biobricks, BBa_K537001, BBa_K537002 and BBa_K537003, have been fully characterized.
2) We are the first team to characterize the function of two different types of theophylline-responsive riboswitches, and this was achieved for two separate coding sequences. These riboswitch designs are improvements over previously-developed iGEM riboswitches.
3) Theophylline-response riboswitch 2 (thRS2-CheZ, BBa_K537002) was capable of significantly higher activation than Theophylline-response riboswitch 1 (thRS1, BBa_K537001) when expressing motility factor CheZ (37-fold vs 4-fold). Moreover, thRS2 showed 6-fold improved motility function over thRS1 and 1-fold increased chemotactic sensitivity to theophylline.
4) Theophylline-responsive riboswitch 2-CheZ (BBa_K537002) represents an ideal biobrick for N-terminal fusion to proteins of interest for theophylline-activated messenger activity. This part could have numerous advantages in several other synthetic biology applications.
